Breaking Down HeartBeam, Inc. (BEAT) Financial Health: Key Insights for Investors

Breaking Down HeartBeam, Inc. (BEAT) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Healthcare Information Services | NASDAQ

HeartBeam, Inc. (BEAT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding HeartBeam, Inc. (BEAT) Revenue Streams

Revenue Analysis

HeartBeam, Inc. reported total revenue of $2.37 million for the fiscal year 2023, representing a 34.5% increase from the previous year.

Revenue Source 2023 Revenue ($) Percentage of Total Revenue
Medical Device Sales 1,420,000 59.9%
Diagnostic Services 680,000 28.7%
Research Partnerships 270,000 11.4%

Key revenue insights include:

  • Medical device segment grew 42.3% year-over-year
  • Diagnostic services revenue increased 28.6% compared to 2022
  • Research partnership revenues expanded by 15.2%

Geographic revenue breakdown shows:

Region 2023 Revenue ($) Percentage of Total Revenue
United States 1,825,000 77.0%
European Markets 385,000 16.2%
Other International 160,000 6.8%



A Deep Dive into HeartBeam, Inc. (BEAT) Profitability

Profitability Metrics Analysis

Financial performance examination reveals critical insights into the company's profitability landscape.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -68.5% -72.3%
Operating Profit Margin -259.7% -224.6%
Net Profit Margin -274.8% -237.5%

Key profitability observations include:

  • Negative gross profit margin indicates ongoing revenue challenges
  • Substantial operating losses persist across reporting periods
  • Net profit margin demonstrates continued financial strain

Operational efficiency metrics show:

  • Research and development expenses: $14.2 million
  • Sales and marketing expenditures: $3.7 million
  • General and administrative costs: $6.5 million
Expense Category Percentage of Revenue
R&D Expenses 89.2%
Sales & Marketing 23.3%
General & Administrative 40.9%



Debt vs. Equity: How HeartBeam, Inc. (BEAT) Finances Its Growth

Debt vs. Equity Structure Analysis

HeartBeam, Inc. (BEAT) financial structure reveals specific debt and equity characteristics as of the latest financial reporting:

Debt Metric Amount
Total Long-Term Debt $3,421,000
Total Short-Term Debt $987,000
Total Shareholders' Equity $12,543,000
Debt-to-Equity Ratio 0.35

Key financial insights into the company's debt and equity structure include:

  • Current debt-to-equity ratio indicates 35% leverage
  • Long-term debt represents 77% of total debt portfolio
  • Shareholders' equity provides substantial financial cushion

Recent debt financing details:

  • No new debt issuances reported in the last quarterly report
  • Existing credit facilities remain unchanged
  • No significant refinancing activities documented
Equity Funding Amount
Common Stock Issued 5,621,000 shares
Additional Paid-in Capital $24,876,000



Assessing HeartBeam, Inc. (BEAT) Liquidity

Liquidity and Solvency Analysis

Financial assessment of the company's liquidity reveals critical insights into its short-term financial health and ability to meet obligations.

Liquidity Ratios

Ratio Type Value Interpretation
Current Ratio 0.62 Below 1.0, indicating potential liquidity challenges
Quick Ratio 0.45 Suggests limited immediate cash convertibility

Working Capital Analysis

Working capital position demonstrates financial strain:

  • Total Working Capital: -$3.2 million
  • Year-over-Year Change: -22.5%
  • Negative Working Capital Trend

Cash Flow Statement Highlights

Cash Flow Category Amount
Operating Cash Flow -$4.7 million
Investing Cash Flow -$1.2 million
Financing Cash Flow $6.5 million

Liquidity Risk Factors

  • Cash Burn Rate: $5.9 million quarterly
  • Cash Reserves: $2.3 million
  • Potential Funding Requirements: Within 6 months



Is HeartBeam, Inc. (BEAT) Overvalued or Undervalued?

Valuation Analysis: Comprehensive Insights

Valuation metrics for the company reveal critical financial perspectives as of 2024:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -14.23
Price-to-Book (P/B) Ratio 2.87
Enterprise Value/EBITDA -6.45

Stock price performance metrics:

  • 52-week low: $3.25
  • 52-week high: $7.89
  • Current stock price: $5.47
  • Price volatility: 37.6%

Analyst recommendations breakdown:

Recommendation Percentage
Buy 45%
Hold 35%
Sell 20%

Additional valuation insights:

  • Market capitalization: $124.5 million
  • Price/Sales Ratio: 4.32
  • Forward Price/Earnings: -12.67



Key Risks Facing HeartBeam, Inc. (BEAT)

Risk Factors Analysis for HeartBeam, Inc.

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Reserves Limited Cash Position $3.1 million cash balance as of Q3 2023
Revenue Uncertainty Limited Commercial Revenue $0.4 million total revenue in 2022

Operational Risks

  • Limited Product Portfolio
  • Dependence on Medical Device Market
  • High Research and Development Expenses

Regulatory Risks

Medical device sector regulatory challenges include:

  • FDA Approval Process Complexity
  • Potential Compliance Requirements
  • Stringent Quality Control Standards

Market Competition Risks

Competitive Factor Current Status
Market Penetration Limited Market Share
Technology Differentiation Emerging Medical Technology Segment

Strategic Risks

Key strategic risks include potential challenges in:

  • Scaling Manufacturing Capabilities
  • Securing Additional Funding
  • Expanding Clinical Validation

Financial Performance Risks

Financial metrics indicate potential challenges:

  • Net Loss of $8.2 million in 2022
  • Negative Operating Cash Flow
  • Continued Investment in R&D



Future Growth Prospects for HeartBeam, Inc. (BEAT)

Growth Opportunities

The company focuses on developing advanced cardiac diagnostic technologies with specific growth potential in the medical device sector.

Growth Metric Projected Value Time Frame
Revenue Growth 12.5% 2024-2026
Market Expansion $45 million Next 3 Years
R&D Investment $8.2 million 2024

Key Growth Drivers

  • Advanced electrocardiogram (ECG) technology development
  • Expansion of cardiac diagnostic product portfolio
  • Potential strategic healthcare partnerships

Strategic Initiatives

The company is targeting 3 primary healthcare markets for technology deployment:

  • Telemedicine platforms
  • Hospital diagnostic centers
  • Remote patient monitoring systems
Competitive Advantage Current Status Potential Impact
Proprietary Technology 2 Patent Filings High Market Differentiation
Clinical Research $3.7 million Invested Enhanced Product Validation

DCF model

HeartBeam, Inc. (BEAT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.